Though Yaccarino does not have experience in health tech, eMed said in a press release that they sought her out for her "undeniable ability to negotiate new partnerships."

Yaccarino has been named CEO of Miami-based eMed Population Health, which calls itself “the leading digital health platform for GLP-1/GIP population health management.” That refers to the class of weight-loss drugs like Wegovy and Ozempic.

The eMed Population Health digital health platform announced Tuesday that former X Chief Executive Officer Linda Yaccarino has been appointed its new CEO.